Insider Transactions Reported by 19 Insiders of Prelude Therapeutics Inc

Symbol
PRLD on Nasdaq
Location
Wilmington, DE

Insiders trading volume in the past year

Prelude Therapeutics Inc executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
ORBIMED ADVISORS LLC Director, 10%+ Owner $38,151,480 22 May 2023
Vaddi Krishna CEO, Director $1,865,335 +$482,347 +35% 04 Feb 2026
Andrew Combs Chief Chemistry Officer $332,485 +$69,250 +26% 04 Feb 2026
Laurent Chardonnet Chief Financial Officer $158,962 01 Mar 2024
Jane Huang President, CMO $153,736 04 Oct 2025
Christopher Pierce EVP and Chief of Business Oper $14,138 02 Sep 2021
Mardi Dier Director 12 Jun 2025
David J. Mauro Chief Medical Officer 05 Oct 2021
Victor Sandor Director 05 Nov 2025
Bryant D. Lim CLO, CFO, Corp Sec. 04 Feb 2026
Martin Babler Director 12 Jun 2025
Paul C. Scherer Director 12 Jun 2025
Peggy Scherle Chief Scientific Officer 04 Feb 2026
Katina Dorton Director 17 Oct 2025
David P. Bonita Director, 10%+ Owner 12 Jun 2025
Brian Piper Chief Financial Officer 25 Aug 2021
Deborah Morosini EVP, Chief of Clinical Affairs 15 Feb 2022
BAKER BROS. ADVISORS LP Director, 10%+ Owner 12 Jun 2025
Paul A. Friedman Director 12 Jun 2025

Recent Insider Transactions by Companies or Individuals for Prelude Therapeutics Inc

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Andrew Combs PRLD Employee Stock Option (right to buy) Award 230,000 230,000 04 Feb 2026 Direct
Krishna Vaddi PRLD Employee Stock Option (right to buy) Award 837,000 837,000 04 Feb 2026 Direct
Peggy Scherle PRLD Employee Stock Option (right to buy) Award 230,000 230,000 04 Feb 2026 Direct
Bryant D. Lim PRLD Employee Stock Option (right to buy) Award 275,000 275,000 04 Feb 2026 Direct
Victor Sandor PRLD Director Stock Option (Right to Buy) Award 121,285 121,285 05 Nov 2025 Direct
Katina Dorton PRLD Director Stock Option (Right to Buy) Award 76,000 76,000 17 Oct 2025 Direct
Jane Huang PRLD Common Stock Tax liability -3.72% -3,355 86,917 04 Oct 2025 Direct
Jane Huang PRLD Common Stock Options Exercise 11.6% 9,375 90,272 04 Oct 2025 Direct
Jane Huang PRLD Restricted Stock Unit Options Exercise -33.3% -9,375 18,750 04 Oct 2025 Direct
Jane Huang PRLD Common Stock Tax liability -3.98% -3,355 80,897 04 Jul 2025 Direct
Jane Huang PRLD Common Stock Options Exercise 12.5% 9,375 84,252 04 Jul 2025 Direct
Jane Huang PRLD Restricted Stock Unit Options Exercise -25% -9,375 28,125 04 Jul 2025 Direct
Baker Bros. Advisors Lp PRLD Non- Qualified Stock Option (right to buy) Award 152,000 76,000 12 Jun 2025 See Footnotes
Victor Sandor PRLD Director Stock Option (Right to Buy) Award 38,000 38,000 12 Jun 2025 Direct
Mardi Dier PRLD Director Stock Option (Right to Buy) Award 38,000 38,000 12 Jun 2025 Direct
Paul A. Friedman PRLD Director Stock Option (Right to Buy) Award 38,000 38,000 12 Jun 2025 Direct
David P. Bonita PRLD Director Stock Option (Right to Buy) Award 38,000 38,000 12 Jun 2025 Direct
Martin Babler PRLD Director Stock Option (Right to Buy) Award 38,000 38,000 12 Jun 2025 Direct
Jane Huang PRLD Common Stock Tax liability -4.29% -3,355 74,877 04 Apr 2025 Direct
Jane Huang PRLD Common Stock Options Exercise 13.6% 9,375 78,232 04 Apr 2025 Direct
Jane Huang PRLD Restricted Stock Unit Options Exercise -20% -9,375 37,500 04 Apr 2025 Direct
Andrew Combs PRLD Common Stock Purchase 26.3% $69,250 $0.6925 100,000 480,123 25 Mar 2025 Direct
Krishna Vaddi PRLD Common Stock Purchase 51% $467,438 $0.6925 675,000 1,999,296 25 Mar 2025 Direct
Krishna Vaddi PRLD Common Stock Purchase 1.15% $10,959 $0.7306 15,000 1,324,296 21 Mar 2025 Direct
Krishna Vaddi PRLD Common Stock Purchase 0.42% $3,950 $0.7294 5,416 1,309,296 20 Mar 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.